Page last updated: 2024-10-30

metformin and Peritoneal Carcinomatosis

metformin has been researched along with Peritoneal Carcinomatosis in 3 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Research Excerpts

ExcerptRelevanceReference
"Metformin-treated mice exhibited suppressed intraperitoneal tumor growth and extended survival, and these effects were lost in mice with severe combined immunodeficiency."1.51Metformin Prevents Peritoneal Dissemination ( Eguchi, S; Hirayama, T; Kanetaka, K; Kobayashi, S; Matsuo, M; Nagata, Y; Nishida, M; Udono, H; Yoneda, A, 2019)
"Metformin treatment enhanced AMPK activation, decreasing the activity of the anabolic factors ribosomal protein S6 and p4EBP-1 and inducing mitochondrial depolarization."1.46MIF/CD74 axis is a target for novel therapies in colon carcinomatosis. ( Belfiore, A; Beznoussenko, GV; Bongarzone, I; Bozzi, F; Caccia, C; Gariboldi, M; Gloghini, A; Leo, E; Leoni, V; Manenti, G; Milione, M; Mironov, AA; Mogavero, A; Pierotti, MA; Pilotti, S; Varinelli, L; Volpi, CC, 2017)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hirayama, T1
Nagata, Y1
Nishida, M1
Matsuo, M1
Kobayashi, S1
Yoneda, A1
Kanetaka, K1
Udono, H1
Eguchi, S1
Sekino, N1
Kano, M1
Matsumoto, Y1
Sakata, H1
Murakami, K1
Toyozumi, T1
Otsuka, R1
Yokoyama, M1
Shiraishi, T1
Okada, K1
Kamata, T1
Ryuzaki, T1
Matsubara, H1
Bozzi, F1
Mogavero, A1
Varinelli, L1
Belfiore, A1
Manenti, G1
Caccia, C1
Volpi, CC1
Beznoussenko, GV1
Milione, M1
Leoni, V1
Gloghini, A1
Mironov, AA1
Leo, E1
Pilotti, S1
Pierotti, MA1
Bongarzone, I1
Gariboldi, M1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Efficacy of metfOrmin in PrevenTIng Glucocorticoid-induced Diabetes in Melanoma, breAst or Lung Cancer Patients With Brain Metastases: the Phase II OPTIMAL Study[NCT04001725]Phase 2110 participants (Anticipated)Interventional2019-10-15Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

3 other studies available for metformin and Peritoneal Carcinomatosis

ArticleYear
Metformin Prevents Peritoneal Dissemination
    Anticancer research, 2019, Volume: 39, Issue:9

    Topics: Animals; Biomarkers; Cell Line, Tumor; Disease Models, Animal; Humans; Immunomodulation; Immunopheno

2019
The Antitumor Effects of Metformin on Gastric Cancer
    Anticancer research, 2018, Volume: 38, Issue:11

    Topics: Adenylate Kinase; AMP-Activated Protein Kinase Kinases; Animals; Antineoplastic Agents; Cell Line, T

2018
MIF/CD74 axis is a target for novel therapies in colon carcinomatosis.
    Journal of experimental & clinical cancer research : CR, 2017, 01-23, Volume: 36, Issue:1

    Topics: AMP-Activated Protein Kinases; Antigens, Differentiation, B-Lymphocyte; Cell Proliferation; Cell Sur

2017
chemdatabank.com